Nathaniel Brooks Horwitz
Biomedical Venture Capitalist
Biotech has entered an era of exponential progress.
Advances in biology have converged with those in computation, engineering and finance to generate biotechnology that once verged on science fiction.
I study the science, business and ethics of biotech. As CEO of Nivien Therapeutics, I led development of an experimental therapy for pancreatic cancer.
I am now the Corporate Development Manager on the Venture Team at RA Capital.
My writing is published by The Washington Post, The New York Times, The Daily Beast, The Boston Globe, The Atlantic and other outlets. My writing does not represent RA Capital. —NBH